ES2554252T3 - Ciclopenta[d]pirimidinas hidroxiladas como inhibidores de la proteína quinasa AKT - Google Patents

Ciclopenta[d]pirimidinas hidroxiladas como inhibidores de la proteína quinasa AKT Download PDF

Info

Publication number
ES2554252T3
ES2554252T3 ES11166125.2T ES11166125T ES2554252T3 ES 2554252 T3 ES2554252 T3 ES 2554252T3 ES 11166125 T ES11166125 T ES 11166125T ES 2554252 T3 ES2554252 T3 ES 2554252T3
Authority
ES
Spain
Prior art keywords
piperazin
pyrimidin
dihydro
cyclopenta
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11166125.2T
Other languages
English (en)
Spanish (es)
Inventor
Ian S. Mitchell
James F. Blake
Rui Xu
Nicholas C. Kallan
Dengming Xiao
Keith Lee Spencer
Josef R. Bencsik
Jun Liang
Brian Safina
Birong Zhang
Christine Chabot
Steven Do
Eli W. Wallace
Anna L. Banka
Stephen T. Schlachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Array Biopharma Inc
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2554252(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2554252T3 publication Critical patent/ES2554252T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
ES11166125.2T 2006-07-06 2007-07-05 Ciclopenta[d]pirimidinas hidroxiladas como inhibidores de la proteína quinasa AKT Active ES2554252T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81871806P 2006-07-06 2006-07-06
US818718P 2006-07-06

Publications (1)

Publication Number Publication Date
ES2554252T3 true ES2554252T3 (es) 2015-12-17

Family

ID=38686743

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11166125.2T Active ES2554252T3 (es) 2006-07-06 2007-07-05 Ciclopenta[d]pirimidinas hidroxiladas como inhibidores de la proteína quinasa AKT
ES11166123.7T Active ES2554228T3 (es) 2006-07-06 2007-07-05 Ciclopenta[d]pirimidinas hidroxiladas como inhibidores de la proteína quinasa AKT
ES07799337T Active ES2372774T3 (es) 2006-07-06 2007-07-05 Ciclopenta[d]pirimidinas hidroxiladas y metoxiladas como inhibidores de la proteína quinasa akt.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES11166123.7T Active ES2554228T3 (es) 2006-07-06 2007-07-05 Ciclopenta[d]pirimidinas hidroxiladas como inhibidores de la proteína quinasa AKT
ES07799337T Active ES2372774T3 (es) 2006-07-06 2007-07-05 Ciclopenta[d]pirimidinas hidroxiladas y metoxiladas como inhibidores de la proteína quinasa akt.

Country Status (34)

Country Link
EP (4) EP2399909B1 (enExample)
JP (4) JP5266216B2 (enExample)
KR (5) KR101578877B1 (enExample)
CN (2) CN102816124A (enExample)
AR (3) AR061842A1 (enExample)
AT (1) ATE524447T1 (enExample)
AU (1) AU2007269060B2 (enExample)
BR (3) BRPI0713923B8 (enExample)
CA (2) CA2836316A1 (enExample)
CL (1) CL2007001993A1 (enExample)
CO (1) CO6150161A2 (enExample)
CR (1) CR10600A (enExample)
CY (1) CY1112117T1 (enExample)
DK (2) DK2049501T3 (enExample)
ES (3) ES2554252T3 (enExample)
HR (1) HRP20110908T1 (enExample)
HU (1) HUE026237T2 (enExample)
IL (2) IL196028A (enExample)
IN (1) IN2014KN02886A (enExample)
MA (1) MA31655B1 (enExample)
MX (4) MX377920B (enExample)
MY (1) MY147364A (enExample)
NO (1) NO342346B1 (enExample)
NZ (3) NZ597647A (enExample)
PL (2) PL2049501T3 (enExample)
PT (1) PT2049501E (enExample)
RS (1) RS52212B (enExample)
RU (2) RU2478632C2 (enExample)
SG (4) SG184706A1 (enExample)
SI (2) SI2402325T1 (enExample)
TW (2) TW201332994A (enExample)
UA (1) UA95641C2 (enExample)
WO (1) WO2008006040A1 (enExample)
ZA (1) ZA200900070B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
KR20150041164A (ko) 2006-07-06 2015-04-15 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 시클로펜타〔ｄ〕피리미딘
WO2008115511A1 (en) 2007-03-20 2008-09-25 Peak Biosciences, Inc. Method for therapeutic administration of radionucleosides
AR067413A1 (es) 2007-07-05 2009-10-07 Genentech Inc Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
KR101624361B1 (ko) 2007-07-05 2016-05-25 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
CN101970415A (zh) 2008-01-09 2011-02-09 阵列生物制药公司 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶
AU2009204025B2 (en) * 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8853216B2 (en) * 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
CN102015708B (zh) 2008-01-09 2014-03-26 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
KR20130132956A (ko) * 2010-12-23 2013-12-05 제넨테크, 인크. 신생물의 치료를 위한 자식증 유도자 및 억제제 조합 요법
RU2635193C2 (ru) * 2011-04-01 2017-11-09 Дженентек, Инк. Биомаркеры для прогнозирования чувствительности к противоопухолевой терапии
CN103841976A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
EP2694072B2 (en) * 2011-04-01 2024-08-07 Genentech, Inc. Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
LT2858989T (lt) 2012-05-17 2020-08-10 Genentech, Inc. Akt inhibuojančio pirimidinil-ciklopentano junginio amorfinė forma, jo kompozicijos ir būdai
ES2668477T3 (es) 2012-05-17 2018-05-18 Genentech, Inc. Proceso de preparación de compuestos de aminoácidos
PL2861583T3 (pl) * 2012-05-17 2016-12-30 Sposób wytwarzania hydroksylowanych związków cyklopentylopirymidyny
SG11201407591PA (en) * 2012-05-17 2015-01-29 Genentech Inc Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
PL2861582T3 (pl) * 2012-05-17 2016-11-30 Sposób wytwarzania hydroksylowanych związków cyklopentylopirymidynowych
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
RU2015127037A (ru) * 2012-12-07 2017-01-11 Дзе Дженерал Хоспитал Корпорейшн Комбинации ингибитора pi3k/akt с ингибитором her3/egfr и способы их применения
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
CN105899492B (zh) * 2013-11-15 2021-08-24 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
CA3190507A1 (en) * 2014-09-26 2016-03-31 F. Hoffmann-La Roche Ag Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
CN116172869A (zh) 2016-08-10 2023-05-30 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
SG10202104386UA (en) 2016-10-28 2021-05-28 Icahn School Med Mount Sinai Compositions and methods for treating ezh2-mediated cancer
CA3092677A1 (en) * 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
US12110295B2 (en) 2018-06-21 2024-10-08 Icahn School Of Medicine At Mount Sinai WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds and methods of use
TWI719765B (zh) 2018-12-19 2021-02-21 美商建南德克公司 使用包含akt抑制劑、紫杉烷及pd-l1抑制劑之組合療法之乳癌治療
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN113272304B (zh) * 2019-01-29 2024-03-29 南京正大天晴制药有限公司 Akt抑制剂
WO2020201073A1 (en) 2019-03-29 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
CA3134491A1 (en) * 2019-04-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use
EP3965824B1 (en) 2019-05-06 2025-01-08 Icahn School of Medicine at Mount Sinai Heterobifunctional compounds as degraders of hpk1
JP2023520140A (ja) * 2020-03-17 2023-05-16 江蘇恒瑞医薬股▲ふん▼有限公司 縮合二環系誘導体、その調製方法及びその医薬的応用
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
CA3175354A1 (en) 2020-06-16 2021-12-23 F. Hoffmann-La Roche Ag Process for making hydroxylated cyclopentylpyrimidine compounds
EP4186902A4 (en) 2020-07-22 2024-06-05 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE SALT, PREPARATION METHOD AND USE THEREOF
TWI750905B (zh) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 噻唑化合物作為蛋白質激酶抑制劑
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
WO2023043869A1 (en) * 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Solid state forms of ipatasertib citrate
CN113788834B (zh) * 2021-09-18 2022-11-29 河南奥思恩医药科技有限公司 2,4-二氯-6,7-二氢-5H-吡咯并[3,4-d]嘧啶盐酸盐的制备方法
CN117677614A (zh) * 2021-12-17 2024-03-08 中国医药研究开发中心有限公司 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
AU2023246862A1 (en) 2022-03-31 2024-10-31 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
EP4604957A1 (en) 2022-10-17 2025-08-27 Astrazeneca AB Combinations of a serd for the treatment of cancer
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
CN120712346A (zh) 2023-01-31 2025-09-26 豪夫迈·罗氏有限公司 具有增加的酮还原酶活性的突变型酮还原酶以及涉及其的方法和用途
EP4643858A1 (en) 2024-04-29 2025-11-05 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of uterine disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL7112938A (enExample) * 1970-09-30 1972-04-05
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
CA2276098C (en) * 1997-01-08 2007-05-08 F. Hoffmann-La Roche Ag Tricyclic benzo[e]isoindoles and benzo[h]isoquinolines
ES2152902B1 (es) * 1999-07-27 2001-08-16 Medichem Sa Procedimiento de obtencion de venlafaxina
PT1315715E (pt) * 2000-08-18 2008-10-30 Millennium Pharm Inc Derivados de quianazolina utilizados como inibidores de quinase
WO2002022607A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1383463B1 (en) * 2001-03-30 2011-04-27 King Pharmaceuticals, Inc. Fused thiophene compounds and use thereof in the treatment of chronic pain
WO2003049678A2 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2473510A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
CA2546754A1 (en) * 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
EP1751133B1 (en) * 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
EP1866822A4 (en) * 2005-03-03 2010-09-01 Burnham Inst Medical Research SCREENING PROCEDURE FOR PROTEIN KINASE B INHIBITORS USING VIRTUAL DOCKING APPARATUS AND COMPOSITIONS AND COMPOSITIONS DISCOVERED THEREFOR
ATE532789T1 (de) * 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
KR20150041164A (ko) * 2006-07-06 2015-04-15 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 시클로펜타〔ｄ〕피리미딘
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы

Also Published As

Publication number Publication date
CN101578273A (zh) 2009-11-11
BR122013028012B8 (pt) 2021-05-25
MY147364A (en) 2012-11-30
IL196028A (en) 2017-02-28
PT2049501E (pt) 2011-12-30
AU2007269060A1 (en) 2008-01-10
ZA200900070B (en) 2010-03-31
NZ610633A (en) 2014-12-24
MA31655B1 (fr) 2010-09-01
AR109424A2 (es) 2018-11-28
IN2014KN02886A (enExample) 2015-05-08
EP2049501A1 (en) 2009-04-22
SG185980A1 (en) 2012-12-28
ES2372774T3 (es) 2012-01-26
AU2007269060B2 (en) 2014-02-20
JP5266216B2 (ja) 2013-08-21
RU2009103900A (ru) 2010-08-20
SG184706A1 (en) 2012-10-30
HK1160134A1 (en) 2012-08-10
BRPI0713923B8 (pt) 2021-05-25
SG10201802127UA (en) 2018-04-27
ES2554228T3 (es) 2015-12-17
RU2012155606A (ru) 2014-06-27
MX2019008117A (es) 2019-09-04
DK2049501T3 (da) 2011-12-12
CA2656622A1 (en) 2008-01-10
CA2836316A1 (en) 2008-01-10
KR20130141717A (ko) 2013-12-26
AR061842A1 (es) 2008-09-24
MX337843B (es) 2016-03-22
SI2402325T1 (sl) 2015-12-31
TW200817373A (en) 2008-04-16
EP2966065A3 (en) 2016-03-02
EP2399909B1 (en) 2015-08-26
BRPI0713923B1 (pt) 2020-09-29
ATE524447T1 (de) 2011-09-15
NZ597647A (en) 2013-08-30
SG188905A1 (en) 2013-04-30
NZ573732A (en) 2012-03-30
HUE026237T2 (en) 2016-06-28
EP2402325B1 (en) 2015-08-26
HRP20110908T1 (hr) 2012-02-29
IL241705A0 (en) 2015-11-30
TW201332994A (zh) 2013-08-16
TWI402266B (zh) 2013-07-21
KR101178672B1 (ko) 2012-09-07
JP2013177470A (ja) 2013-09-09
EP2399909A1 (en) 2011-12-28
NO20090581L (no) 2009-04-06
KR20130029364A (ko) 2013-03-22
CR10600A (es) 2009-02-20
EP2402325A3 (en) 2012-06-13
IL196028A0 (en) 2009-09-01
MX377920B (es) 2025-03-11
NO342346B1 (no) 2018-05-07
KR20150051240A (ko) 2015-05-11
KR20090030333A (ko) 2009-03-24
UA95641C2 (xx) 2011-08-25
CL2007001993A1 (es) 2008-06-20
AR093810A2 (es) 2015-06-24
BR122013028005B8 (pt) 2021-05-25
CO6150161A2 (es) 2010-04-20
MX366319B (es) 2019-07-05
JP5836294B2 (ja) 2015-12-24
CA2656622C (en) 2017-09-12
JP2013091670A (ja) 2013-05-16
EP2049501B1 (en) 2011-09-14
BRPI0713923A2 (pt) 2013-07-02
JP2009542723A (ja) 2009-12-03
HK1160638A1 (en) 2012-08-10
CN102816124A (zh) 2012-12-12
JP2014231530A (ja) 2014-12-11
PL2402325T3 (pl) 2016-01-29
KR20140093291A (ko) 2014-07-25
RU2478632C2 (ru) 2013-04-10
CN101578273B (zh) 2012-11-14
KR101578877B1 (ko) 2016-02-22
EP2966065A2 (en) 2016-01-13
DK2402325T3 (en) 2015-12-07
CY1112117T1 (el) 2015-11-04
HK1126768A1 (en) 2009-09-11
EP2402325A2 (en) 2012-01-04
BR122013028005B1 (pt) 2021-04-06
BR122013028012B1 (pt) 2021-04-06
SI2049501T1 (sl) 2012-01-31
WO2008006040A1 (en) 2008-01-10
PL2049501T3 (pl) 2012-02-29
RS52212B (sr) 2012-10-31
MX2008016202A (es) 2009-02-11
KR101495408B1 (ko) 2015-02-25

Similar Documents

Publication Publication Date Title
ES2554252T3 (es) Ciclopenta[d]pirimidinas hidroxiladas como inhibidores de la proteína quinasa AKT
US20240293558A1 (en) Kras inhibitor conjugates
JP7724911B2 (ja) 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法
ES2935392T3 (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas JAK
ES2372955T3 (es) Ciclopenta[d]pirimidinas como inhibidores de la proteína cinasa akt.
TWI746178B (zh) 製備作為jak激酶抑制劑之萘啶化合物之方法
KR102399848B1 (ko) 신규한 jak1 선택적 억제제 및 그 용도
ES2299637T3 (es) Derivados de pirrolidina y piperidina como antagonistas de nk1.
ES2258485T3 (es) Antagonistas selectivos de neuroquinina.
AU781438B2 (en) VLA-4 inhibitor compounds
WO2024040080A1 (en) Kras inhibitor conjugates
CA2656566C (en) Dihydrofuro pyrimidines as akt protein kinase inhibitors
CA2656364C (en) Dihydrothieno pyrimidines as akt protein kinase inhibitors
CA2939786A1 (en) Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use
TW202506692A (zh) 吡啶并嘧啶衍生物及其用途
RU2733406C2 (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
ES2401685T3 (es) Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT
TW201607930A (zh) 作為ｔ７９０ｍ／ｗｔ－ｅｇｆｒ的選擇性和不可逆的激酶抑制劑的５－氨基－４－氨甲醯基－吡唑化合物及其用途
EP2247578B1 (en) Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
EA047776B1 (ru) Соединение гетероарилкарбоксамида
AU2014201211B2 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CN116803984A (zh) 一种靶向热休克蛋白110kDa（HSP110）抑制剂及其应用
US20140357644A1 (en) Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
HK1150201B (en) Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
HK1150201A (en) Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors